Zentralinstitut Fuer Seelische Gesundheit — Clinical Trial Site

27 Registered trials

11 Currently recruiting

Organisation

Zentralinstitut Fuer Seelische Gesundheit

Location

Mannheim, Germany

Identifier

ORG-100013535

Address

Luisenring J 5, 68159, Germany

Departments

Abteilung für Molekulares Neuroimaging
Addiction Medicine
Central Institute of Mental Health
Central Institute of Mental Health (CIMH)
Clinic of Psychiatry and Psychotherapy
Department of Molecular Neuroimaging
Gerontopsychiatrie
Klinik f. Psychiatrie und Psychotherapie
Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters
Klinik für Psychosomatik
Klinik für Psychosomatik und Psychotherapeutische Medizin
Molecular Neuroimaging
N/A
NA
Psychiatrie und Psychotherapie des Kindes- und Jugendalters
Psychiatry and Psychotherapy
Zentralinstitut für Seelische Gesundheit
Zentralinstitut für Seelische Gesundheit Zentralambulanz
ZI

Clinical trials at this site (27)

Search interface

Clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder Pending

2024-510873-11-00 Borderline personality disorder 4
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) Pending

2024-516805-22-00 Major Depressive Disorder 5
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-13
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheime… Recruiting

2023-509807-34-00 Early Alzheimer’s Disease (Mild Cognitive Impairment an 4 2024-08-12
Long Term Study of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder Recruiting

2023-503545-67-00 Tourette's Disorder 5 2024-04-30
Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia Recruiting

2024-513222-30-00 Adolescent patient (13-17 years of age) with Schizophre 5 2020-02-20
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1) Recruiting

2025-522313-38-00 Alcohol Use Disorder 5 2026-03-06
A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518008-33-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-12
A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder Recruiting

2024-519270-40-00 Major Depressive Disorder 5 2025-10-30
A study to test how BI 3031185 is tolerated by people with borderline personality disorder or attention-deficit/hyperactivity disorder. Recruiting

2024-514296-17-00 Attention deficit hyperactivity disorder 3 2025-08-05
A trial to investigate the effects of Cannabidiol plus Naltrexone on alcohol craving in patients with alcohol dependence Recruiting

2024-518164-12-00 Alcohol dependence 4 2025-06-16
Enhancing social skills in schizophrenia spectrum disorders – two-arm, double-blind, randomized clinical trial investigating oxytocin vs. p… Recruiting

2023-509433-40-00 schizophrenia or other primary psychotic disorders (SSD 4 2024-08-29
Patient- and care-related benefits of amyloid PET imaging (ENABLE) Recruiting

2023-503705-10-00 Dementia in Pick disease 6 2024-08-19
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Gen… Ended

2024-513572-17-00 Generalized Anxiety Disorder (GAD) 5 2025-08-20
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim… Ended

2023-506183-13-00 Alzheimer’s Disease 4 2024-03-29
A Phase 3 clinical study to investigate the effects of BAN2401 in patients with Early Alzheimer's Disease. Ended

2024-510887-22-00 Mild cognitive impairment due to Alzheimer's disease or 5 2019-09-30
A prospective, multicentre, randomised, double-dummy, double-blind, placebo-controlled 3-way Phase III study to investigate the efficacy and… Halted

2022-502903-31-00 Patients with ADHD (according to ICD-10 / DSM-5) 5 2025-11-05
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-6404… Halted

2023-505096-68-00 Preclinical Alzheimer’s Disease 4 2025-01-14
Enhancing recovery in early schizophrenia: A study comparing cannabidiol and placebo as add-on to standard antipsychotic treatment. Halted

2024-517198-26-00 Remitted early phase schizophrenia 4 2017-02-17
A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodec… Ended

2023-505086-83-00 Tourette Syndrome 4 2024-07-10
Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients with Treatment Resistant Depression Ended

2024-513457-70-00 Treatment-Resistant Depression (TRD) 4 2023-09-08
Ecopipam Tablets to Study Tourette’s Disorder in Children, Adolescents and Adults (D1AMOND) Ended

2023-503494-38-00 Tourette’s Disorder 5 2023-07-20
Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibili… Ended

2024-517537-40-00 Posttraumatic Stress Disorder 4 2022-04-06
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended

2024-511560-93-00 Schizophrenia 5 2022-03-29